Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | CD74 | P04233 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23028378 | 0.78 | NOTUM (0.58) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL16271200 | 0.75 | P2RX7 (0.67) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL16090354 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL12959177 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL17039112 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL541468 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL2629357 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL6030190 | 0.74 | NOTUM (0.58) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL2889068 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 | |
| SCHEMBL12443625 | 0.74 | P2RX7 (0.55) | P2RX7NOTUMMAOAL3MBTL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | claimed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | claimed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | claimed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | claimed |
| US-11885818-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-112492881-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-103748067-A | Process for producing aminopropyne or enaminone | AGENCY SCIENCE TECH & RES | 2014-04-23 | — | — | CN | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | SRMS, PTMS, MMAB | P2RX7 3227/4885NOTUM 212/4885MAOA 854/4885 |
| US-11885818-B2 | Reagent for mass spectrometry | SRMS, PTMS, MMAB | P2RX7 3227/4885NOTUM 212/4885MAOA 854/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | P2RX7 3964/4885NOTUM 702/4885MAOA 2475/4885 |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | P2RX7 3841/4885NOTUM 929/4885MAOA 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.